AmerisourceBergen to Launch Digital Therapeutics Platform to Facilitate Access to Innovative Products
Several developers plan to pilot DTx Connect, which aims to reduce barriers that physicians and patients face across the ordering and fulfillment of digital therapeutics and diagnostics
Conshohocken, Pa. (July 27) – As the pipeline of digital therapeutics (DTx) continues to expand, AmerisourceBergen today announced plans to launch DTx Connect, a fully integrated ordering, dispensing and fulfillment platform that aims to facilitate patient access to physician-ordered digital therapeutics and diagnostics. The platform, which seamlessly integrates with electronic medical records (EMR), enables physicians to easily access and order prescription and non-prescription DTx through their e-prescribing workflow and subsequently monitor patient fulfillment.
A rapidly growing category within digital health, DTx delivers clinical interventions directly to patients via software to treat, manage or prevent a broad spectrum of diseases and disorders, including behavioral health conditions and diabetes. The products, which occasionally require a prescription, can be used as standalone therapies or in combination with other treatments or devices. Digital therapeutics diverge from other digital health tools, in part, because they must be cleared or certified by regulatory bodies to support claims of risk, efficacy and intended use. The market is projected to grow at a compound annual growth rate of nearly 25% from 2022 to 2030 in the United States.
Several digital health companies plan to pilot the platform, including Mahana Therapeutics, a leading developer of prescription digital therapeutics designed to empower patients with chronic health conditions, and Videra Health, an AI-assisted video assessment and remote patient monitoring platform.
Conshohocken, Pa. (July 27) – As the pipeline of digital therapeutics (DTx) continues to expand, AmerisourceBergen today announced plans to launch DTx Connect, a fully integrated ordering, dispensing and fulfillment platform that aims to facilitate patient access to physician-ordered digital therapeutics and diagnostics. The platform, which seamlessly integrates with electronic medical records (EMR), enables physicians to easily access and order prescription and non-prescription DTx through their e-prescribing workflow and subsequently monitor patient fulfillment.
A rapidly growing category within digital health, DTx delivers clinical interventions directly to patients via software to treat, manage or prevent a broad spectrum of diseases and disorders, including behavioral health conditions and diabetes. The products, which occasionally require a prescription, can be used as standalone therapies or in combination with other treatments or devices. Digital therapeutics diverge from other digital health tools, in part, because they must be cleared or certified by regulatory bodies to support claims of risk, efficacy and intended use. The market is projected to grow at a compound annual growth rate of nearly 25% from 2022 to 2030 in the United States.
Several digital health companies plan to pilot the platform, including Mahana Therapeutics, a leading developer of prescription digital therapeutics designed to empower patients with chronic health conditions, and Videra Health, an AI-assisted video assessment and remote patient monitoring platform.
Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.
Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.